相关实验视频

Updated: Jul 17, 2025

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

伦瓦丁尼布诱导的瘤溶解综合征在晚期肝细胞癌中

Manjeet Kumar Goyal¹, Arshdeep Singh¹, Yogesh Kumar Gupta¹

¹Department of Gastroenterology, Dayanand Medical College & Hospital, Ludhiana, Punjab, India.

ACG case reports journal

|September 7, 2023

概括

一名患有肝癌的患者在开始服用伦瓦提尼布治疗后不久就出现了瘤溶解综合征 (TLS). 迅速的医疗干预成功管理了这种情况,强调了需要保持警的必要性.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

肝细胞癌 (HCC) 是一种主要的肝癌.
伦瓦提尼布是一种用于治疗HCC的向疗法.

研究的目的:

报告Lenvatinib诱导的瘤溶解综合征病例在患有HCC的患者中.
强调早期识别和管理TLS的重要性.
为了突出TLS的潜在风险,即使在短期的伦瓦替尼治疗后.

主要方法:

一份病例报告详细介绍了一个48岁的男性患者,患有HCC.
描述了患者在7天的伦瓦提尼布治疗后TLS的发展情况.
干预措施概述,包括补水,阿洛普林醇,拉斯布里卡斯和电解质管理.

主要成果:

患者在开始服用伦瓦提尼布后一周内发展了TLS.
对TLS的干预导致了临床改善.
患者得到了成功的治疗,并从医院出院.

结论:

伦瓦替尼布治疗可以在HCC患者中导致TLS.
早期发现和迅速管理TLS对于有利的结果至关重要.
对于TLS的警是有必要的,即使在短期内在HCC中使用lenvatinib.

关键词:

肝细胞癌是肝细胞癌.伦瓦提尼布 (Lenvatinib) 是一种药物.瘤溶解综合征是什么

更多相关视频

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...